Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-Alpha Inhibitor, TOS-358, in Adult Subjects With Select Solid Tumors

NCT05683418 is registered in ClinicalTrials.gov with Totus Medicines as lead sponsor.

NCT NCT05683418
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05683418 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-Alpha Inhibitor, TOS-358, in Adult Subjects With Select Solid Tumors
Lead sponsor
Totus Medicines
Phase
Phase 1
Overall status
Recruiting
Start date
February 15, 2023
Completion date
December 31, 2027
Enrollment
241 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

hr+/her2-negative breast cancer